Schedule 13D ownership disclosure

CATALYST BIOSCIENCES, INC.

Security class unavailable · CUSIP: 14888D109

Event date: 2017-05-18

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
1,243
Percent of class
0.0000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001144204-18-008668
Form type
SC 13D
Filer
GYRE THERAPEUTICS, INC.
CIK
CIK 1124105
Filed
Feb 14, 2018
Reporting period
May 18, 2017
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub